Homologous recombination deficiency (HRD) is characterized by the inability of tumor cells to accurately repair double-stranded DNA breaks via the homologous recombination repair (HRR) pathway. This impairment leads to genomic instability, a hallmark of several high-grade serous ovarian cancers (HGSOCs), and results in sensitivity to PARP inhibitor (PARPi) therapy.
Key Clinical Trials & HRD-Targeted Outcomes in Ovarian Cancer
For oncologists managing ovarian cancer, comprehensive HRD testing—incorporating both BRCA mutation status and genomic instability profiling—is critical for:
- Identifying patients most likely to benefit from PARPi-based therapy
- Optimizing maintenance strategies in both first-line and recurrent disease
References
https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1586
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1405361/full#B21